With current treatment strategies with all-trans-retinoic acid (ATRA) in combination with anthracycline based chemotherapy, approximately 70%–80% of patients with newly diagnosed APL carrying PML/RARα achieve long-term remission and are probably cured. The gene discussed is RARA; the disease is acute promyelocytic leukemia.